Yahoo Finance5d
Why Eli Lilly Stock Topped the Market Today
This indicates there remains much potential in the molecules used as the basis for obesity drugs -- semaglutide for Novo Nordisk, and tirzepatide in the case of Eli Lilly. Waxing bullish about the ...
Eli Lilly's head of obesity talks weight-loss innovations for 2025 — from an Ozempic-like pill to a triple-threat shot
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Business Insider3d
Eli Lilly & Co (LLY) Gets a Buy from Citi
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...
The Motley Fool4d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Eli Lilly is experiencing explosive growth thanks to its diabetes and obesity treatments. Beyond weight loss, the company is quietly building a fast-growing oncology business. This is an enormous ...
Business Insider3d
Morgan Stanley Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price target of $1,146.00. The company’s shares closed ...